文献速递肝病消化道肿瘤与早癌

肝细胞癌长期生存者的临床病程与预后

Clinical Course and Prognosis of Long-Term Survivors of Hepatocellular Carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2025-02-16

本研究基于韩国国民健康保险服务数据库的回顾性队列,纳入2008年1月至2010年12月新诊断的35,348例肝细胞癌患者并随访至2018年12月。11,514例(32.6%)生存满5年,其额外1年、3年、5年累积生存概率分别为90.7%、77.6%、68.4%;以治愈性治疗为首治者额外5年累积生存概率高于非治愈性治疗者(74.5% vs. 64.2%)。

要点

  • 35,348例肝细胞癌患者中11,514例(32.6%)生存满5年。
  • 长期生存者额外5年累积生存概率为68.4%,首治为治愈性治疗者高于非治愈性治疗者(74.5% vs. 64.2%)。
  • 长期生存者中44.4%在诊断5年后接受肝细胞癌再治疗,其额外5年累积生存概率为54.9%。

核心结论

  • 相当比例肝细胞癌患者生存超过5年,治愈性治疗与良好结局相关。

研究设计与样本

  • 回顾性队列研究,使用韩国国民健康保险服务数据库数据。
  • 共纳入2008年1月至2010年12月新诊断的35,348例肝细胞癌患者,随访至2018年12月。

主要发现

  • 35,348例患者中11,514例(32.6%)在诊断后生存满5年。
  • 长期生存者(≥5年)较非生存者(<5年)女性比例更高、年龄更轻、乙型肝炎病毒病因更常见、肝硬化及糖尿病和高血压更少、接受治愈性治疗更频繁。
  • 长期生存者的额外1年、3年、5年累积生存概率分别为90.7%、77.6%、68.4%。
  • 以治愈性治疗为首治者额外5年累积生存概率为74.5%,高于非治愈性治疗者的64.2%。
  • 长期生存者中44.4%在诊断5年后接受肝细胞癌再治疗,该组额外5年累积生存概率为54.9%;长期生存者第二原发恶性肿瘤的总体5年和10年累积概率分别为15.36%和27.54%,最常见为前列腺癌,其次为结直肠癌和胰腺癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: This study investigated the long-term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis. METHODS: This retrospective cohort study used data from the Korean National Health Insurance Service database. A total of 35,348 subjects newly diagnosed with HCC between January 2008 and December 2010 were followed up until December 2018. RESULTS: A total of 11,514 (32.6%) survived for 5 years after diagnosis of HCC among 35,348 patients diagnosed with HCC. Long-term survivors (≥ 5 years) had a higher proportion of females, younger age, more frequent aetiology of hepatitis B virus, less frequent liver cirrhosis, diabetes mellitus and hypertension, and received curative treatment more frequently than nonsurvivors (< 5 years). The additional 1-, 3- and 5-year cumulative survival probabilities were 90.7%, 77.6% and 68.4% respectively. Patients who underwent curative treatment as the first treatment for HCC showed a higher additional 5-year cumulative survival probabilities than those treated with noncurative therapy (74.5% vs. 64.2%). Among the long-term survivors, 44.4% underwent HCC retreatment 5 years after HCC diagnosis. The additional 5-year cumulative survival probability was 54.9% in the HCC retreatment group. The overall 5- and 10-year cumulative probabilities of second primary malignancies in long-term survivors were 15.36% and 27.54% respectively. The most frequent second primary malignancy was prostate cancer, followed by colorectal and pancreatic cancers. CONCLUSION: Our study highlights that a significant proportion of patients with HCC achieve long-term survival beyond 5 years, with favourable outcomes associated with curative treatments.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kim SS, Lee J, Ahn SB, et al. Clinical Course and Prognosis of Long-Term Survivors of Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2025. PMID: 39955712. doi:10.1111/apt.70004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。